As advanced therapies drive increasing market consolidation, the US giant Agilent Technologies has acquired the Canadian contract development and manufacturing organization (CDMO) BIOVECTRA for $925 million.
As a strategic brand consultant at ramarketing, Laura combines her extensive background in clinical research with strategic leadership and creative expression.
Rusan Pharma Private Limited has announced that its active pharmaceutical ingredient (API) manufacturing facility in Ankleshwar, Gujarat, has been granted Good Manufacturing Practice (GMP) approval by the FDA.
Avista, a New York-based private equity firm focused on healthcare, and Hamilton Lane, a global private markets investment management firm, have announced that funds managed by Hamilton Lane have acquired a significant equity interest in Cosette Pharmaceuticals...
Japanese medical devices company, Nipro Medical Corporation, a giant in the healthcare and medical device industry, has announced a major investment of $397.8 million to establish its first North American manufacturing center of excellence in Greenville,...
At the DIA 60th annual conference in San Diego, senior editor Liza Laws from Outsourcing Pharma had the opportunity to sit down with Marwan Fathallah, President and CEO of DIA.
Psychedelic therapeutics have rapidly gained popularity in the pharma industry in a matter of just a few years. Here are five psychedelic drug discovery startups that have received investment this year.
Integrated DNA Technologies (IDT) is doubling down on its commitment to innovation with the launch of a new 25,000-square-foot synthetic biology facility in Coralville, Iowa.
During her teenage years, Dr. Jasmina Jankicevic harbored a passion for researching and advocating improved methods to maintain health and well-being for both children and adults.
Ketaki Patwardhan, a global technical developer at Roquette, has built a remarkable career in the pharmaceutical industry by leveraging her curiosity and passion for science.
In an exclusive interview, Akash Bakshi, CEO of YourChoice Therapeutics, delves into the inspiration and journey behind developing a hormone-free birth control pill for men.
The growing opioid crisis in the US has been exacerbated by various systems and biases, preventing individuals from accessing critical treatments like methadone and buprenorphine.
Preclinical results show promise for Tyra Bioscience’s lead drug candidate for the treatment for hypochondroplasia, a condition for which there are currently no therapeutic options available.
CatSci, a UK-based innovation partner for the development of pharmaceutical manufacturing processes, will be expanding its service offering with the acquisition of Reach Separations.
The US Food and Drug Administration (FDA) has approved Verona Pharma’s Ohtuvayre (ensifentrine), marking a significant milestone in the treatment of chronic obstructive pulmonary disease (COPD).
During a panel discussion held at DIA Global in San Diego this week, which was moderated by Peter Wahl, vice president and global head of scientific affairs at CorEvitas, industry experts delved into the integration of real-world data (RWD) and advanced...
Cellibre, a pioneer in sustainable biochemical manufacturing, has received a $2 million grant from the National Center for Complementary and Integrative Health (NCCIH) at the National Institutes of Health (NIH).
Thermo Fisher’s new state-of-the-art ultra-cold facility in Bleiswijk, Netherlands, aims to accelerate advanced therapies development by offering a comprehensive range of cold and ultra-cold services.
Hikma Pharmaceuticals PLC has made a significant announcement, marking the US launch of Combogesic IV, an intravenous, opioid-free pain relief medication providing a multimodal approach to managing pain in adults.
In a groundbreaking development, Systech, a subsidiary of Markem-Imaje and Dover, has introduced a turnkey manual aggregation and rework solution tailored for pharmaceutical manufacturers, CMOs, CDMOs, re-packagers, and wholesalers.
In an inspiring conversation with Liza Laws, Dr. Michael Giles, MD, and chief executive officer of Sonara Health, shares the innovative journey of creating a platform to enhance the accessibility of methadone treatment for opioid use disorder patients.
As Roquette's US Innovation Center marks its first anniversary, Roquette took the opportunity to reflect on its interesting journey and achievements over the past year.
Stella Vnook has founded several biotech companies, including Oral BioLife, a biotechnology firm specializing in pioneering therapies for dental diseases.
UK based Celadon Pharmaceuticals Plc, that specializes in the development, production, and sale of breakthrough cannabis-based medicines, announced that it has begun shipping to the US.
A new report from Access to Medicine Foundation gives the advice to ensure the few promising antimicrobials in development reach patients on the frontlines of drug resistance.
Can Montreal's Centech startup, Install-VASc, transform ultrasound-guided catheter insertion?
Continuing the Montreal startup ideas presented to OSP and others during a recent trip, this was another idea to come from Centech, the non-profit organization helping people develop their ideas in a bid to making them a reality.
SamaCare, a leading cloud-based patient access platform for specialty medications, today announced the closure of an oversubscribed $17 million Series B investment round.
Today (May 14) Everest Medicines, a biopharmaceutical company focused on progressive medicines and vaccines, announced the successful launch of small molecule Nefecon, a delayed-release capsule, in China, with the first prescription issued.
Roquette, a global leader in plant-based ingredients and a key provider of pharmaceutical and nutraceutical excipients, announced today (May 14) the launch of its innovative Lycagel Flex hydroxypropyl pea starch premix for softgel capsules.
Sanofi, a global pharmaceutical giant, has announced a significant investment of over €1 billion ($1.08 billion) in new bioproduction capacity at three manufacturing sites in France.
A collaborative report released today (May 9) by Medicines Discovery Catapult (MDC), sheds light on the challenges facing the life sciences sector amidst recent economic turbulence.
PCI Pharma Services, a global leader in contract development and manufacturing, has embarked on the installation of crucial equipment for its latest sterile fill-finish facility at its Bedford, NH campus in Philadelphia.
Renée Aguiar-Lucander, CEO of Calliditas, is driving the advancement and launch of TARPEYO – the company’s medication targeting rare disease IgA nephropathy. We spoke with Renée about her journey from investment banking to science and the joy of bringing...
In an extensive and enlightening chat with Prasad Raje, the CEO of LGM Pharma, OSP gained profound insights into the company's trajectory within the pharmaceutical industry.
Last month, OSP was excited to write about One2Treat, a progressive startup specializing in digital health solutions, which has launched a forward-thinking approach aimed at tackling key challenges in the biopharma industry.
Today (April 24), Astellas Pharma Inc. revealed that XTANDITM (enzalutamide) has received a label extension from the European Commission, marking it as the inaugural and only novel hormone therapy endorsed for high-risk biochemical recurrent non-metastatic...
At CPhI North America, Quotient Sciences is looking forward to reconnecting with its customers and giving them a preview of how we are looking to expand Translational Pharmaceutics further within the US.
Torbay Pharmaceuticals is a sterile injectable contract manufacturer and licence holder based in Devon, UK. We spoke with CEO Emma Rooth about the company's heritage and how it is striving to support the U.S. market.
LGM Pharma is a leading CDMO provider of comprehensive API sourcing and drug product contract development and manufacturing solutions to the pharmaceutical, biotechnology, and compounding pharmacy industries.
Earlier this week, Charles River Laboratories International, Inc. revealed its Alternative Methods Advancement Project (AMAP), which it said is a strong initiative aimed at changing drug discovery and development by exploring alternatives to animal testing.
GSK plc unveiled encouraging results from its pivotal Eagle-1 phase 3 trial for gepotidacin, a potential breakthrough oral antibiotic for uncomplicated urogenital gonorrhoea (GC) in adolescents and adults.
